Protagonist Therapeutics

Positive phase 3 data for JNJ-2113 (icotrokinra) showed significant skin clearance in moderate-to-severe plaque psoriasis patients aged 12 and older, with 64.7% achieving IGA 0/1 and 49.6% PASI 90 at week 16 compared to placebo. The results validate JNJ-2113's potential as a best-in-class oral treatment.

Protagonist Therapeutics announces positive phase 3 trial results for JNJ-2113, an oral peptide for moderate-to-severe psoriasis, showing significant skin clearance and tolerability. The ICONIC-LEAD and ICONIC-TOTAL studies demonstrated efficacy and safety, with 74.1% achieving IGA scores of 0/1 and 64.9% achieving PASI 90 by Week 24. Further studies on psoriatic arthritis and ulcerative colitis are planned for 2025.

Protagonist Therapeutics announced positive phase 3 results for JNJ-2113, an oral peptide targeting IL-23 receptor, showing significant skin clearance in moderate to severe plaque psoriasis, with a favorable safety profile.

Johnson & Johnson's experimental pill, icotrokinra, developed with Protagonist Therapeutics, showed significant skin clearance in 66% of moderate-to-severe plaque psoriasis patients after four months in a Phase 3 trial. The drug aims to match injectable treatments' effectiveness with oral convenience, targeting the IL-23 receptor. While efficacy appears comparable to Stelara and potentially superior to Sotyktu and Otezla, it may not replace Skyrizi and Tremfya due to lower effectiveness. J&J plans to submit approval applications with detailed results from the ICONIC-LEAD and ICONIC-TOTAL studies.

Johnson & Johnson's once-daily oral IL-23 inhibitor icotrokinra met efficacy objectives in phase 3 ICONIC-LEAD trial for moderate to severe plaque psoriasis, with 74.1% achieving clear or almost clear skin at week 24. The drug showed similar safety profiles to placebo and could offer a patient-friendly alternative to injectable biologics. J&J plans to submit data to regulators and compete with Bristol-Myers Squibb's TYK2 inhibitor Sotyktu.

Icotrokinra (JNJ-2113) met co-primary endpoints in moderate to severe plaque psoriasis, with 74% achieving clear or almost clear skin at week 24. Results to be presented at medical congresses.

Johnson & Johnson announced positive Phase 3 results for icotrokinra (JNJ-2113), showing significant skin clearance and tolerability in moderate to severe plaque psoriasis patients. Icotrokinra, a once-daily oral peptide targeting the IL-23 receptor, met co-primary endpoints of PASI 90 and IGA 0/1 at week 16, with response rates improving through week 24. Safety data aligned with previous studies, and further Phase 3 trials are ongoing.

TD Cowen analyst Tara Bancroft maintains a Buy rating on Protagonist Therapeutics (PTGX) with a $65.00 price target, anticipating positive Phase III ICONIC-LEAD and ICONIC-TOTAL psoriasis study results. Bancroft highlights the company's strategic focus on high PASI 90 scores and an upcoming oral IL-17 candidate, positioning it favorably against existing treatments.

Protagonist Therapeutics to present final Phase 2 REVIVE study data on rusfertide for polycythemia vera at the 66th ASH Annual Meeting in San Diego, December 7-10, 2024.

Peptide Therapeutics Market to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, driven by increasing prevalence of cancer and metabolic disorders, and advancements in drug delivery systems.